Acute Lymphoblastic Leukemia

Overview

STAY TUNED FOR 2026 EVENT INFORMATION.

Oncology fellows and pediatric oncology fellows who are nominated to attend the Acute Lymphoblastic Leukemia Fellows Scholar Program (ALLFSP) are selected by their program directors. Ideal candidates for the program are dedicated to enhancing their understanding of acute lymphoblastic leukemia (ALL) across various age groups and to advancing their knowledge of treatment methods. During this multi-day meeting, fellows attend interactive learning sessions with expert faculty and participate in breakout workshops in which they discuss clinical cases with colleagues from across the United States. Each participant is required to prepare and present one brief case study on an ALL-related topic of their choice.

Activity Description

The ALLFSP is an intensive multi-day course designed for adult and pediatric hematology/oncology fellows to expand their education and understanding of the complex and evolving therapeutic space of ALL. The primary objective for the third installment of this program is to provide fellows with a thorough review of the current management for ALL across diverse patient populations. Additionally, the agenda aims to foster discussions on evaluating and differentiating current treatment options, refining treatment approaches and care plans, the future trajectory of therapy, and the questions that are driving research.

Who Should Attend

Fellows who are nominated to attend the ALLFSP are selected by their program directors. Ideal candidates for the program are at least in their second year of an adult or pediatric hematology/oncology fellowship (exceptions for first-year fellows may be considered on a case-by-case basis) and are committed to furthering their knowledge of the treatment of ALL. During this multi-day meeting, fellows attend interactive learning sessions with expert faculty and participate in breakout workshops in which they discuss clinical cases with colleagues from across the United States. Each registrant is required to prepare and present one brief case study on an ALL-related topic of their choice. Attendees of the 2025 ALLFSP will receive a detailed electronic handout and other resources related to the treatment of ALL.

Travel

Each participant will receive a travel scholarship on-site at ALLFSP.

• Attendees are responsible for their airfare to and from Orlando.
• Attendees will reserve a hotel room via a secure hotel website once registration is confirmed.

*Travel scholarships are available for all learners, supported by CEC.

Case Study

All registrants are required to present an ALL-related clinical case during their assigned case study breakout session. All case study presentations must be submitted in advance in PowerPoint format. The presentation should include no more than 6–8 slides, with the expectation of approximately 10 minutes for both presentation and discussion. Case study submission requirements will be emailed to fellows following registration.

Learning Objectives

1. Evaluate the present and prospective use of asparaginase in various age categories among individuals with ALL
2. Differentiate available asparaginase products, including their dose, route, formulation, pharmacokinetics, and toxicity profiles
3. Utilize strategies to monitor serum asparaginase levels to properly distinguish among asparaginase infusion reactions, clinical and subclinical hypersensitivity, and silent inactivation
4. Incorporate the latest prospective data in the treatment landscape for AYA ALL to refine treatment approaches for this heterogeneous age group
5. Implement multifaceted risk-versus-benefit assessments as part of ALL management in the older adult population
6. Identify the non-clinical drivers of treatment response, including outcomes related to age differences, ethnicity, and location
7. Create risk-stratified treatment plans for R/R ALL based on unique clinical characteristics of disease
8. Assess the management of Ph+ ALL encompassing current therapeutic choices and future strategies
9. Evaluate clinical strategies for the treatment of ALL using a case-based approach with in-sights from colleagues, faculty, and patients/caregivers